People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TV2 HOLDING Co | — | Other Health Care | Series C | $173.7M | $228.6M | 2015 |
| MedAvail, Inc. | — | Other Health Care | Series C | $97.0M | $2.0B | 2020 |
| MedAvail Holdings, Inc. | — | Pharmaceuticals | Series B | $52.9M | $678.6M | 2022 |
MICHAEL R. KRAMER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside MICHAEL R. KRAMER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert C. Faulkner | 2 | 2 |
| Ryan Drant | 1 | 24 |
| David Kim | 1 | 17 |
| Robert Thomas | 1 | 8 |
| DANIEL MOORE | 1 | 6 |
| Gerard Van Hamel Platerink | 1 | 6 |
| Douglas Roeder | 1 | 5 |
| JAMES SHAPIRO | 1 | 5 |
| Arun Ramamoorthy | 1 | 5 |
| Robert J Hariri | 1 | 5 |
| Jake Nunn | 1 | 5 |
| Jake R. Nunn | 1 | 4 |
| Robert Whirley | 1 | 4 |
| Douglas A. Roeder | 1 | 4 |
| Helen Ciesielski | 1 | 3 |
| MICHAEL KRAMER | 1 | 3 |
| James Scopa | 1 | 3 |
| Ryan D. Drant | 1 | 3 |
| Steven Harrison | 1 | 2 |
| Peter Levy | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.